South Africa's Biovac to start making Pfizer-BioNTech COVID-19 vaccine in early 2022 - exec




  • In US
  • 2021-12-06 13:59:02Z
  • By Reuters
 

KIGALI (Reuters) -South Africa's Biovac Institute will start making Pfizer-BioNTech's COVID-19 vaccine early next year after receiving the drug substance from Europe, a Pfizer executive said on Monday.

Biovac's "fill and finish" deal with Pfizer, announced in July, will make it one of the few companies processing COVID-19 shots in Africa, where many countries have struggled to access sufficient doses during the pandemic.

"We expect that the Cape Town facility will be incorporated into our supply chain by the end of this year," Patrick van der Loo, Pfizer regional president for Africa and the Middle East, told a conference in Kigali on vaccine manufacturing in Africa.

"Biovac will obtain the drug substance from facilities in Europe and manufacturing of finished doses will commence early in 2022," he said, appearing by video link.

Large Western pharmaceutical companies including Pfizer have been widely criticised for not doing enough to facilitate vaccine production in developing countries.

In July Pfizer's CEO urged World Trade Organization members not to support a waiver on some intellectual property rights for COVID-19 vaccines - a proposal by South Africa and India.

Biovac's deal with Pfizer covers the final stages of manufacturing, where the vaccine is processed and put into vials, but does not represent a transfer of the intellectual property underpinning the vaccine.

Van der Loo listed what he described as historical challenges faced by pharmaceutical companies on the continent, saying these explained the difficulties in kickstarting local vaccine manufacturing.

Among them were irregular power and water supplies, which have been an issue in South Africa over the years.

"Last year ... water was rationed, which made it very difficult both practically but also ethically to obtain and use large quantities of water for trial runs through the equipment as part of our start-up tech transfer phase," he said, referring to operations at the Biovac facility.

(Reporting by Clement Uwiringiyimana in Kigali and Estelle Shirbon in London,Writing by Alexander Winning; Editing by Louise Heavens and Emelia Sithole-Matarise)

COMMENTS

More Related News

Finclusion raises $20M to build out credit-led neobank offering across Africa
Finclusion raises $20M to build out credit-led neobank offering across Africa

The digital banking space in Africa is taking shape as neobanks on the continent grow in numbers like their global counterparts. Venture capital bet from...

Pfizer to boost COVID-19 pill production with French deal
Pfizer to boost COVID-19 pill production with French deal
  • US
  • 2022-01-17 11:27:59Z

PARIS (Reuters) -Pfizer will add a production facility for its antiviral COVID-19 pill in France as part of a plan to invest 520 million euros ($594 million)...

Unilever signals pursuit of GSK consumer arm; shares fall
Unilever signals pursuit of GSK consumer arm; shares fall
  • US
  • 2022-01-17 07:28:52Z

Unilever signalled on Monday it would pursue a deal for GlaxoSmithKline's consumer healthcare business, calling it a "strong strategic fit" but its shares...

Italy reports 149,512 coronavirus cases on Sunday, 248 deaths
Italy reports 149,512 coronavirus cases on Sunday, 248 deaths
  • US
  • 2022-01-16 16:29:28Z

MILAN (Reuters) -Italy reported 149,512 COVID-19 related cases on Sunday, after 180,426 the day before, the health ministry said, while the number of deaths ...

Italy reports 180,426 coronavirus cases on Saturday, 308 deaths
Italy reports 180,426 coronavirus cases on Saturday, 308 deaths
  • US
  • 2022-01-15 16:35:50Z

Italy reported 180,426 COVID-19 related cases on Saturday, after 186,253 the day before, the health ministry said, while the number of deaths fell to 308...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US